Erythropoietin deficiency decreases vascular stability in mice.
about
Bone marrow-derived cells in ocular neovascularization: contribution and mechanismsThe unfolded protein response in retinal vascular diseases: implications and therapeutic potential beyond protein foldingThe pleiotropic effects of erythropoietin in infection and inflammationInhibition of oxygen-induced ischemic retinal neovascularization with adenoviral 15-lipoxygenase-1 gene transfer via up-regulation of PPAR-γ and down-regulation of VEGFR-2 expressionMolecular mechanisms of action and therapeutic uses of pharmacological inhibitors of HIF-prolyl 4-hydroxylases for treatment of ischemic diseasesHIF-1alpha and HIF-2alpha are differentially activated in distinct cell populations in retinal ischaemiaDifferential modulation of angiogenesis by erythropoiesis-stimulating agents in a mouse model of ischaemic retinopathyAstrocyte-derived vascular endothelial growth factor stabilizes vessels in the developing retinal vasculatureThe mouse retina as an angiogenesis model.Quantification of oxygen-induced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesisComputer-aided quantification of retinal neovascularization.Erythropoetin receptor expression in the human diabetic retinaGhrelin modulates physiologic and pathologic retinal angiogenesis through GHSR-1aSuppression of retinal neovascularization by erythropoietin siRNA in a mouse model of proliferative retinopathyVitreal levels of erythropoietin are increased in patients with retinal vein occlusion and correlate with vitreal VEGF and the extent of macular edema.Retinopathy of prematurity: current concepts in molecular pathogenesis.NADPH oxidase, NOX1, mediates vascular injury in ischemic retinopathy.Bim is responsible for the inherent sensitivity of the developing retinal vasculature to hyperoxia.Overexpression of pigment epithelium-derived factor inhibits retinal inflammation and neovascularization.Vascular endothelial growth factor-B gene transfer exacerbates retinal and choroidal neovascularization and vasopermeability without promoting inflammation.Effect of brimonidine on retinal and choroidal neovascularization in a mouse model of retinopathy of prematurity and laser-treated ratsNeurodegeneration: An early event of diabetic retinopathy.The effect of erythropoietin on the severity of retinopathy of prematurityRetinopathy of prematurity: understanding ischemic retinal vasculopathies at an extreme of life.The retinal pigment epithelium: something more than a constituent of the blood-retinal barrier--implications for the pathogenesis of diabetic retinopathy.Retinal expression of Wnt-pathway mediated genes in low-density lipoprotein receptor-related protein 5 (Lrp5) knockout mice.Diabetic retinopathy: targeting vasoregressionErythropoietin contrastingly affects bacterial infection and experimental colitis by inhibiting nuclear factor-κB-inducible immune pathwaysTreatment of retinopathy of prematurity: a review of conventional and promising new therapeutic optionsSurvival and proliferative roles of erythropoietin beyond the erythroid lineage.New-onset maternal gestational hypertension and risk of retinopathy of prematurity.Double anti-angiogenic and anti-inflammatory protein Valpha targeting VEGF-A and TNF-alpha in retinopathy and psoriasis.Endogenous erythropoietin varies significantly with inflammation-related proteins in extremely premature newborns.Twist1 controls lung vascular permeability and endotoxin-induced pulmonary edema by altering Tie2 expression.Sirtuin1 over-expression does not impact retinal vascular and neuronal degeneration in a mouse model of oxygen-induced retinopathy.Hypoxia-inducible factor-1 drives annexin A2 system-mediated perivascular fibrin clearance in oxygen-induced retinopathy in mice.Hyperoxia therapy of pre-proliferative ischemic retinopathy in a mouse modelSystemic administration of erythropoietin inhibits retinopathy in RCS rats.Possibility of enhanced risk of retinal neovascularization in repeated blood donors: blood donation and retinal alteration.Intervention with an erythropoietin-derived peptide protects against neuroglial and vascular degeneration during diabetic retinopathy
P2860
Q26765959-1EAB8561-041B-4ABF-BCEA-5DC128C92E6EQ26852080-3A398A9F-5110-4B8A-99F0-A0CB7E3183D0Q26864149-D8B0EC82-F932-498F-83C0-9C656DB46DFDQ27332433-25FD8377-2AD9-4914-BD7B-685802D72F88Q28297656-E6D75299-439A-447E-BF2B-62CCF8CDFF3CQ28474375-FB969AB2-4772-46B9-8A41-C5C7020EFB3DQ28750073-8F6FF3FF-9D79-4241-A373-3D09E77A9976Q28750081-1FE3927D-E8B0-41F7-AAFF-78ED3D1F99CFQ30495106-CE0A7B45-7348-4256-9D07-F43B38ED98C9Q30542079-BD75C7BB-1A80-45AB-94FC-652CC946A7ABQ30577340-C6E831A9-6E2B-4B40-AFA8-8632A0060422Q30908819-85F2174D-8A63-46B6-B240-44286171F793Q30968571-141B760D-53B1-4314-A24C-3AACE0A2EBC5Q33379554-E7413ABE-FC7F-4063-A033-06EC0552BBF1Q33593437-B03A5DE7-2133-4359-8AB7-5875906738B0Q33606227-32695D6C-1465-4C3F-8A43-2BC96B126BC9Q33632781-0D1B55C5-D7DB-4FF6-A723-D3E285199C47Q33737167-3BE65839-40A8-4F71-87C5-58BEE8A159BEQ33808055-2B07899A-4D86-472A-84DC-81EFF3E2559BQ33834038-CAE3E646-C58B-4E4A-B705-F9BA6CCE4C47Q33868753-CD85604F-704D-414B-9747-32E54F28A375Q33887925-FC596D9B-AA63-40A5-9A95-3FEA8AB4C71FQ33891194-BF1083FE-1930-4021-8602-D85DFD848D5CQ34090125-5DD1D804-F61D-4C77-97EF-3AB59211D3E9Q34100527-A50CB70D-9239-4840-929F-73A6FBA3FEB3Q34137571-054EA04A-2BA6-4F57-90CA-79C30C16E4C5Q34448837-758A5A09-D544-4F98-BE9D-E898EB2899DDQ34544348-D7FD556A-BA0A-40C2-8F95-D73BDA9B9B44Q34704214-50C34C91-13EB-4BE2-8471-668DE2543EB0Q34725972-0E2DD484-CCB8-4351-8E35-422AD28D2B95Q34735110-42DB257F-AD08-4B1C-9C37-2ED38235B39AQ34800330-DC8C0403-7512-4364-B309-BF2DE16B8CE9Q34849821-9EDA806D-4508-4085-8CB0-6661AF70984CQ34984424-BA34B6B7-EE06-46BF-A6E3-D9D61FF9E22DQ35085010-3ACD64AB-40D4-486E-81F5-F61CC24846AAQ35212416-9C37BC32-2FA6-491B-BEC0-539916F18A54Q35221114-133063EE-34C1-4EEC-B7D2-B20C6ECB40F8Q35224135-6CA5B7E7-07DD-416C-8375-2483EB3C242CQ35225120-18AEFB90-772E-4DE3-BE0C-91CEFF010287Q35405149-217D314A-17A6-4815-B588-26C8CBEC5FCC
P2860
Erythropoietin deficiency decreases vascular stability in mice.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Erythropoietin deficiency decreases vascular stability in mice.
@ast
Erythropoietin deficiency decreases vascular stability in mice.
@en
type
label
Erythropoietin deficiency decreases vascular stability in mice.
@ast
Erythropoietin deficiency decreases vascular stability in mice.
@en
prefLabel
Erythropoietin deficiency decreases vascular stability in mice.
@ast
Erythropoietin deficiency decreases vascular stability in mice.
@en
P2093
P2860
P356
P1476
Erythropoietin deficiency decreases vascular stability in mice
@en
P2093
Christopher M Aderman
Lois E H Smith
P2860
P304
P356
10.1172/JCI33813
P407
P577
2008-02-01T00:00:00Z